Chorioretinal Atrophic Lesions Evolution in Patients with Quiescent Myopic Choroidal Neovascularization Followed for More Than 10 Years

Figures & data

Table 1 Demographics, CNV Characterization and Respective Implemented Treatment

Parameter	Total Subjects (n = 36)
Age, years	62.11 ± 15.12
Gender, female	26 (72.2%)
Involved eye, left	20 (55.6%)
Spherical equivalent, diopters	−11.81 ± 3.55
Total follow-up time, years	12.38 ± 2.68
Systemic comorbidities
Dyslipidemia	15 (41.7%)
Systemic hypertension	12 (33.3%)
Thyroid disease with hypothyroidism	7 (19.4%)
Diabetes	5 (13.9%)
Malignancy	5 (13.9%)
CNV lesions classification
Classic	32 (88.9%)
Minimally classic	3 (8.3%)
Occult	1 (2.8%)
CNV lesions location
Subfoveal	27 (75%)
Juxtafoveal	7 (19.4%)
Extrafoveal	2 (5.6%)
Total treatment time, years	3.32 ± 3.30
Number of intravitreal injections per eye	12.50 ± 12.40
Bevacizumab	16 (44.4%)
Ranibizumab	7 (19.4%)
Both bevacizumab and ranibizumab	13 (36.1%)
Previous treatment with PDT	9 (25%)
Total suspension of treatment time, years	7.72 ± 2.88

Notes: Categorical data are presented as n (%). Continuous data are presented as mean ± standard deviation (SD), or median ± interquartile range for skewed data.

Abbreviations: CNV, choroidal neovascularization; PDT, photodynamic therapy.

Figure 1 Graphic representation of the BCVA variation (on the right, (a)) at baseline (0), when anti-VEGF was suspended (1) and at last visit (2). On the left (b), the evolution of chorioretinal atrophic areas is displayed at the two last time points (1 and 2).

Figure 2 FAF images of two illustrative example patients from our cohort. FAF area at baseline (FAF0) and at the last visit (FAF2).

Figure 3 Correlations between BCVA at baseline (0), when anti-VEGF was suspended (1) and at last visit (2). We found a substantial positive correlation between BCVA0 and BCVA1 (0.675, p<0.001), a moderate positive correlation between BCVA0 and BCVA2 (0.437, p=0.008), and an almost perfect positive correlation between BCVA1 and BCVA2 (0.835, p<0.001). BCVA in ETDRS letters.

Figure 4 Linear correlation between atrophic area after anti-VEGF treatment suspension (FAF 1) and at last visit (FAF 2) on the right (a), and between FAF 1 and atrophic area growth rate (mm2/year) on the left (b). We found an almost perfect positive correlation between FAF1 and FAF2 (0.901, p<0.001) and a substantial positive correlation between FAF1 and atrophic area growth rate (0.673, p<0.001). FAF area in mm²; atrophic area growth rate in mm²/year.

Figure 5 Linear correlation BCVA and atrophic area after anti-VEGF treatment suspension (BCVA1 vs FAF 1) and at last visit (BCVA2 vs FAF 2). We found a moderate negative correlation between BCVA1 and FAF1 (−0.410, p=0.013) and a reasonable correlation between BCVA2 and FAF2 (−0.341, p=0.042). BCVA in ETDRS letters; FAF area in mm².

Data Sharing Statement

Access to any supplemental information is available upon reasonable request.